Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001193125-23-030129
Filing Date
2023-02-09
Accepted
2023-02-09 16:30:57
Documents
2

Document Format Files

Seq Description Document Type Size
1 SC 13D/A d461604dsc13da.htm SC 13D/A 40869
2 EX-99.1 d461604dex991.htm EX-99.1 14488
  Complete submission text file 0001193125-23-030129.txt   56957
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filed by) CIK: 0000886163 (see all company filings)

EIN.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A
SIC: 2834 Pharmaceutical Preparations

Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Subject) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-88828 | Film No.: 23606699
SIC: 2834 Pharmaceutical Preparations